O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy  by Mi, Wenyi et al.
Biochimica et Biophysica Acta 1812 (2011) 514–519
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isO-GlcNAcylation is a novel regulator of lung and colon cancer malignancy
Wenyi Mi 1, Yuchao Gu 1, Cuifang Han, Haiyan Liu, Qiong Fan, Xinling Zhang, Qi Cong, Wengong Yu ⁎
Key Laboratory of Marine Drugs, Chinese Ministry of Education, Key Laboratory of Glycoscience & Glycotechnology of Shandong Province, School of Medicine and Pharmacy,
Ocean University of China, 5 Yushan Road, Qingdao 266003, China⁎ Corresponding author. Key Laboratory of Marine
Education, School of Medicine and Pharmacy, Ocean
Road, Qingdao 266003, China. Tel.: +86 532 82031680;
E-mail address: yuwg66@ouc.edu.cn (W. Yu).
1 These authors contributed equally to this work.
0925-4439/$ – see front matter. Crown Copyright © 20
doi:10.1016/j.bbadis.2011.01.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 August 2010
Received in revised form 4 January 2011
Accepted 12 January 2011





ImmunohistochemistryO-GlcNAc is a monosaccharide attached to serine or threonine hydroxyl moieties on numerous nuclear
and cytoplasmic proteins; O-GlcNAcylation is dynamically regulated by O-GlcNAc transferase (OGT) and
O-GlcNAcase (OGA). Although recent studies have shown that O-GlcNAcylation plays essential roles in
breast cancer progression, it is also necessary to know whether O-GlcNAcylation is involved in other
types of human cancer. In this study, O-GlcNAcylation levels and the expressions of OGT and OGA in
human lung and colon cancer tissues were examined by immunohistochemistry analysis. We found that
O-GlcNAcylation as well as OGT expression was signiﬁcantly elevated in the cancer tissues compared
with that in the corresponding adjacent tissues. Additionally, the roles of O-GlcNAcylation in the
malignancy of lung and colon cancer were investigated in vitro. The results showed that O-GlcNAcylation
markedly enhanced the anchorage-independent growth of lung and colon cancer cells; O-GlcNAcylation
could also enhance lung and colon cancer invasion in a context-dependent manner. All together, this
study suggests that O-GlcNAcylation might play important roles in lung and colon cancer formation and
progression, and may be a valuable target for diagnosis and therapy of cancer.
Crown Copyright © 2011 Published by Elsevier B.V. All rights reserved.1. Introduction
O-linked β-N-acetylglucosamine (O-GlcNAc) is a monosaccharide
attached to serine or threonine hydroxyl moieties on nuclear
and cytoplasmic proteins. Similar to protein phosphorylation, O-
GlcNAcylation can be attached or removed dynamically in response to
changes in the cellular environment triggered by stress, hormones, or
nutrients [1]. O-GlcNAc transferase (OGT) catalyzes the transfer of
GlcNAc from UDP-GlcNAc to serine/threonine residues of target
proteins while O-GlcNAcase (OGA) catalyzes removal of O-GlcNAc.
This dynamic and reversible modiﬁcation is emerging as a key
regulator of various cellular and disease processes [1–3].
It has been proposed that O-GlcNAcylationmight be a regulator of
cancer, based on the O-GlcNAcylation of many oncogenes and tumor
suppressors [4–6]. In recent years, the roles of O-GlcNAcylation in
breast cancer have been investigated. Reginato's group has reported
that the metastatic breast cancer cell lines showed an increase in
OGT protein expression and O-GlcNAcylation, suggesting that higher
O-GlcNAcylation level might be beneﬁcial to breast cancer cells [7].
In our group, immunohistochemistry analysis indicated that the
global O-GlcNAcylation level in breast tumor tissues is elevatedDrugs, Chinese Ministry of
University of China, 5 Yushan
fax: +86 532 82033054.
11 Published by Elsevier B.V. All rigsigniﬁcantly, compared with that in the corresponding adjacent
tissues; moreover, O-GlcNAcylation was signiﬁcantly enhanced in
the metastatic lymph nodes compared to their corresponding
primary tumor tissues [8]. It has also been demonstrated that O-
GlcNAcylation could enhance breast cancer tumorigenesis, invasion
and metastasis in some breast cancer cells [7,8].
Colon cancer and lung cancer are the most common cancers in the
world. To investigate whether O-GlcNAcylation also plays roles in colon
and lung cancers, O-GlcNAcylation level was examined in human lung
cancer tissues and colon cancer tissues by immunohistochemistry
analysis. Additionally, the global O-GlcNAcylation level was altered
throughOGA inhibition andOGT silencing in lungand colon cancer cells,
and the effects of O-GlcNAcylation on cancer malignancy were
investigated.
2. Materials and methods
2.1. Cell cultures
Human lung epithelial carcinoma cell line A549 was cultured in F12K
medium supplemented with 10% fetal bovine serum (FBS). The human
non-small cell lung carcinoma cell line H1299was cultured in RPMI-1640
medium supplemented with 10% FBS. The human colon tumor cell line
HT29wasmaintained in DMEMmedium supplementedwith 10% FBS. To
elevate O-GlcNAcylation level, cells were treated with 5 μM Thiamet-G
(a selective OGA inhibitor, synthesized as described previously [9]) for
24 h or the indicated time period.hts reserved.
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The shRNA-expressing lentiviral vector pLKO.1-puro, Δ8.2 packaging
plasmid construct (encoding gag, pol, rev) and VSV-G plasmid were
provided by Dr. William C. Hahn (Harvard Medical School and Dana-
Farber Cancer Institute, Boston, MA). The human shOGT-targeting
sequence is GGATGCTTATATCAATTTAGG. The synthesized oligos were
annealed and inserted into the AgeI/EcoRI double digested pLKO.1-puro
vector. A control shRNA oligo, which does not match with any known
human coding cDNA, was used as control (named shCtrl).
2.3. Viral production and infection of target cells
Lentiviruses of pLKO.1-based vectorswere producedby cotransfection
with Δ8.2 and VSV-G plasmids into HEK293T cells. The stable infected
cells were selected with 8 μg/ml puromycin for 2 weeks.
2.4. Soft agar assay
The soft agar assay was performed as described [10]. Brieﬂy, cells
(1×104) were suspended in 1 ml top agar medium (the corresponding
mediumsuppliedwith 0.4%agar). The cell suspensionwas then overlaid
onto 1.5 ml bottom agarmedium (the correspondingmedium supplied
with 0.8% agar) in six-well tissue culture plates in triplicate. Fresh
mediumwas added to plates every 3 days as a feeder layer. On the day
15, the colonies were captured at ×40 magniﬁcations.
2.5. Immunoblotting
Cells were lysed in lysis buffer [50 mM Tris–HCl (pH 7.4), 150 mM
NaCl, 1% NP40, 1 mM EDTA, 1 mM Na3VO4, 10 mM NaF] containing a
protease inhibitor cocktail (Roche, NJ, USA) and 5 μMPUGNAc (Toronto
Research Chemicals Inc., Canada). Protein samples (50 μg) were
separatedby12%SDS-PAGEand transferred to Immobilon-Pmembranes
(Millipore,MA, USA). Antibodies toO-GlcNAcylation (CTD110.6; Abcam,
Cambridge, UK), OGT (F-12; Santa Cruz, CA, USA), and GAPDH (SantaFig. 1.O-GlcNAcylation level is elevated in the lung and colon tumor tissues. Representative lu
The staining intensity was graded by an experienced pathologist and analyzed by FromowiCruz, CA, USA) were used for detection by ECL-detecting reagent
(Amersham Biosciences, Buckinghamshire, England).
2.6. Immunohistochemical studies
A lung cancer tissuemicroarray (TMA, OD-CT-RsLug03-002; Shanghai
Outdo Biotech Co., China) was constructed with formalin-ﬁxed parafﬁn-
embedded 31 lung cancer tissues and their corresponding adjacent lung
tissues. A colon cancer TMA (OD-CT-DgCol03-002; Shanghai Outdo
Biotech Co.) was constructed with formalin-ﬁxed parafﬁn-embedded 31
colon cancer tissues and their corresponding adjacent lung tissues.
Immunohistochemistry was performed on the TMAs by using DAKO
Liquid DAB Substrate Chromogen System (Dako Cytomation, CA, USA)
and a monoclonal mouse antibody against O-GlcNAc (RL2; Afﬁnity
Bioreagents, CO, USA; 1:200), OGA (L-14; Santa Cruz, CA, USA; 1:50),
and OGT (F-12; Santa Cruz, CA, USA; 1:100). Fromowitz standard was
used to semi-quantitatively assess the staining of O-GlcNAcylation,
OGA, and OGT [11,12].
2.7. Cell invasion assay
These procedures were performed as described [10]. Cell invasion
was assayed using Transwell chambers (6.5 mm; Corning, NY, USA)
with 8 μm pore membranes, the upper face of the membrane was
covered with 70 μl Matrigel (1 mg/ml) (BD Biosciences, NJ, USA). The
lower chamber was ﬁlled with 600 μl lower medium (medium with
20% FBS). Cells (2×104) were suspended with 100 μl upper medium
(mediumwith 1% FCS) and plated into the upper chamber. After 20 h,
the number of cells appearing by crystal violet staining on the
undersurface of the polycarbonate membranes was scored visually in
ﬁve random ﬁelds at ×100 magniﬁcation.
2.8. Statistic analysis
Data were analyzed by the Student's t-test using the SPSS 11.0
software program. Pb0.05 was considered statistically signiﬁcant.
Data are present as the mean±standard error of the mean (SEM).ng (A) and colon tumor tissue sections (B) stained with an antibody to O-GlcNAc (RL2).
tz standard. ***Pb0.001 (paired sample t-test), mean±SEM.
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3.1. O-GlcNAcylation level is elevated in the lung and colon tumor tissues
To investigate the role of O-GlcNAcylation in lung and colon cancer
malignancy, a lung cancer TMA and a colon cancer TMA were ﬁrstly
used to analyze the O-GlcNAcylation by immunohistochemistry. The
lung cancer TMA was constructed with formalin-ﬁxed parafﬁn-
embedded 31 lung squamous cell carcinoma tissues and their
corresponding adjacent lung tissues (Supplementary Table S1). The
colon cancer TMA was constructed with formalin-ﬁxed parafﬁn-embed-
ded 31 colon adenocarcinoma tissues and their corresponding adjacent
colon tissues (withmucosa chronic inﬂammation) (Supplementary Table
S2). The representative tissue sections stained with an antibody to O-
GlcNAc (RL2) were shown in the left and middle panels of Fig. 1A and B.
The intensity of O-GlcNAcylation immunostaining was analyzed by
Fromowitz standard, and the results indicated that O-GlcNAcylation was
markedly enhanced in lung and colon cancer tissues compared with that
in the adjacent tissues (the right panels of Fig. 1A and B).Fig. 2. The expressions of OGT and OGA were examined in the lung and colon tumor tissues.
antibody to OGT. (C and D), Representative lung (C) and colon tumor tissue sections (D) s
pathologist and analyzed by Fromowitz standard. ***Pb0.001 (paired sample t-test), mean3.2. The expression of OGT is elevated in the lung and colon tumor tissues
To reveal themechanismunderlying the elevation of O-GlcNAcylation
in lung and colon tumor tissues, the expressions of OGT and OGA were
analyzed by immunohistochemistry in the same lung and colon tumor
tissues and their correspondingadjacent tissues. The results indicated that
OGT expressionwas conspicuously elevated in both lung and colon tumor
tissues compared with their corresponding adjacent tissues (Fig. 2A and
B); then, we searched the Oncomine database (www.oncomine.org) and
found that OGTmRNA levels were also signiﬁcantly elevated in both lung
and colon tumor tissues (data not shown) [13–16]. However, the
expression of OGA showed no signiﬁcant difference between the tumor
tissues and their corresponding adjacent tissues (Fig. 2C and D).
3.3. O-GlcNAcylation is elevated or decreased in the lung and colon
cancer cell lines
To determine whether O-GlcNAcylation played an important role in
lung and colon cancer malignancy, the level of O-GlcNAcylation was(A and B), Representative lung (A) and colon tumor tissue sections (B) stained with an
tained with an antibody to OGA. The staining intensity was graded by an experienced
±SEM.
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the lung and colon cancer cell lines. The expression of OGT shRNA
(shOGT) drastically reduced OGT expression as well as O-GlcANcylation
level in A549, H1299 andHT29 cells (Fig. 3A). On the other hand, a highly
potent and selective OGA inhibitor (Thiamet G) could markedly elevate
the O-GlcNAcylation of A549, H1299 and HT29 cells (Fig. 3B). These two
approaches enabled us to identify the effects of O-GlcNAcylation on the
malignant properties of lung and colon cancer cells.
3.4. O-GlcNAcylation enhances the anchorage-independent growth of
lung and colon cancer cells
To investigate whether O-GlcNAcylation affected proliferation and
anchorage-independent growth of lung and colon cancer cells, MTT
and soft agar colony assays were performed. OGT silencing and
Thiamet-G treatment did not signiﬁcantly affect the proliferation of
A549, H1299 and HT29 (data not shown). Soft agar colony assays
showed that OGT silencing markedly reduced the colony formation
ability, and Thiamet-G treatment signiﬁcantly increased colony
formation ability of A549, H1299 and HT29 cells (Fig. 4). These
results indicated O-GlcNAcylation was important for maintaining the
anchorage-independent growth of lung and colon cancer cells.
3.5. The effects of O-GlcNAcylation on the invasion of lung and colon
cancer cells
Recently, our and others' labs have found that O-GlcNAcylation
could enhance the invasion and metastasis of breast cancer cells. ToFig. 3. O-GlcNAcylationwas decreased byOGT silencing or elevatedby Thiamet-G treatment.
(A), TheexpressionofOGTandO-GlcNAcylation level inOGTsilencedA549,H1299, andHT29
cells was detected by immunoblotting with antibody to OGT and to O-GlcNAc (RL2). (B),
A549, H1299, and HT29 cells were pre-treated or not with 5 μM Thiamet-G for 24 h and
applied for immunoblotting with an antibody to O-GlcNAc (RL2).investigate whether O-GlcNAcylation affects lung and colon cancer
cells invasion, invasion assays were carried out. As shown in Fig. 5, the
invasion abilities of A549 (Fig. 5A), but not H1299 and HT29 cells
(Fig. 5B and C), were signiﬁcantly enhanced by Thiamet-G treatment
and inhibited by OGT silencing, suggesting that O-GlcNAcylation
might play important roles in lung and colon cancer metastasis in a
context-dependent manner.
4. Discussion
Herewe have demonstrated that O-GlcNAcylation of lung and colon
cancer tissues is signiﬁcantly elevated compared with that in the
corresponding adjacent tissues, consistentwith our previous results and
others that O-GlcNAcylation was elevated in the primary breast tumor
tissues and breast cancer cells [7,8]. One unansweredquestion iswhat is
responsible for the augmentation of O-GlcNAcylation in the cancer
tissues. Theoretically, an increase of O-GlcNAcylation level could be
causedby elevatedUDP-GlcNAcconcentration, reducedOGAexpression
as well as its catalytic activity, and/or increased OGT expression and
activity. A physiological hallmark of tumors is the use of aerobic
glycolysis (also known as the Warburg effect) instead of oxidative
phosphorylation to produce ATP [1]. This metabolic pathway has
elevated rates of glucose uptake [17]. Additionally, cancer cells are
addicted to glutamine; the rate of glutamine consumption in tumors is
10-fold higher than in normal cells [18,19]. Approximately 2–3% of total
cellular glucose is funneled into the hexosamine biosynthetic pathway
(HBP) to produce UDP-N-acetylglucosamine (UDP-GlcNAc) [20]. The
HBP shares its ﬁrst two steps with glycolysis; ﬁrst, hexokinase
phosphorylates glucose to produce glucose 6-phosphate, which is
then converted into fructose 6-phosphate by phosphoglucoseisomerase.
At this point the pathways diverge, GFAT1 catalyzes the irreversible
transfer of the amino group from glutamine and the isomerization of
fructose 6-phosphate into glucosamine 6-phosphate and glutamate [1].
Intuitively, increased cellular glucose as well as glutamine shunted into
the HBPwould increase UDP-GlcNAc levels. O-GlcNAcylation is catalyzed
by OGT, whose activity is tightly dependent on the substrate concentra-
tion of UDP-GlcNAc in the cell. Previously, Reginato's group reported
tumor cell lines thatmimicmetastatic tumors showed an increase in OGT
protein expression; moreover, they found that OGT mRNA levels were
signiﬁcantly elevated in breast tumor tissues [7]. Our data indicate that
OGT expression is markedly enhanced in cancer tissues compared with
that in corresponding adjacent tissues; coordinately we found that OGT
mRNA levelswere also signiﬁcantly elevated inboth lungandcolon tumor
tissues. The OGT expression elevation as well as probably raised activity
could result in O-GlcNAcylation elevation in tumor tissues. At the same
time, the opposing enzyme (OGA)was evaluated at the protein level. The
results show that the expression of OGA has no signiﬁcant difference
between the tumor tissues and their corresponding adjacent tissues.
Unfortunately, the difﬁculty of the amount of available fresh resection
samples limited our study to the UDP-GlcNAc concentration, OGT and
OGA activity in cancer tissues. This is an important issue that we are
attempting to address in future studies. Nonetheless, our data
indicate that the increase of OGT expression may be one of the main
causes of O-GlcNAcylation elevation in tumor tissues.
Several studies have shown that O-GlcNAcylation acts as a key cellular
regulator in cell cycle and survival. Deletion ofOGT in ES cells is lethal [21],
and OGT tissue-speciﬁcmutation results in the loss of O-GlcNAcylation in
speciﬁc tissues and causes T-cell apoptosis and ﬁbroblast growth arrest
[22]. Itwas also reported thatOGT inhibitionpreventedG2/Mtransition in
Xenopus laevis oocytes [23]. Recently, Caldwell et al. showed that
reduction of O-GlcNAcylation through RNA interference of OGT in breast
cancer cells leads to inhibitionof tumorgrowthboth in vitroand in vivo [7].
Anchorage-independent growth is thought to be among the fundamental
properties of malignant cells [10]. In the present study we demonstrated
that O-GlcNAcylation signiﬁcantly enhanced anchorage-independent
growth of lung and colon cancer cells, suggesting that O-GlcNAcylation
Fig. 4.O-GlcNAcylation enhances anchorage-independent growth of lung and colon cancer cells. The anchorage-independent growth of A549 (A), H1299 (B) and HT29 (C) cells were
analyzed by soft agar assay. (5×103 cells/well).
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Additionally, our data indicate O-GlcNAcylation enhances the invasion of
some types of cancer cells. So, the roles and mechanisms of O-
GlcNAcylation in cancer invasion might be context-dependent and
inﬂuenced by cell type and oncogenic events acquired during the course
of tumor evolution.
In response to multiple forms of injury, cells remodel their
metabolic and signaling pathways to promote survival—the so-called
cellular stress response [24,25]. As a stress sensor, O-GlcNAcylation
levels increase rapidly and dynamically in multiple mammalian cell
lines in response to numerous forms of cellular stress (heat stress,
oxidative stress, hypoxia, ischemia reperfusion injury, and trauma
hemorrhage injury) [26]. Notably, raising O-GlcNAcylation levels by
either inhibition of O-GlcNAcase, or overexpression of OGT, rendered
cells more thermotolerant [27]. O-GlcNAcylation is protective for cellsFig. 5. The effect ofO-GlcNAcylationon lungand colon cancer cells invasion. (A) Thiamet-G trea
cell invasion. (B and C), Thiamet-G treatment and OGT silencing have no effect on the cell invasunder oxidative stress through FOXO4 O-GlcNAcylation and enhanc-
ing its transcriptional activity [28]. Conversely, lowering levels of O-
GlcNAcylation by altering OGT levels or blocking the HBP sensitized
cells to apoptotic stimuli [26]. The inappropriate proliferation of
primary tumor cells is challenged by multiple layers of mechanisms
that suppress tumor formation. Several of these barriers include
reactive oxygen species, extracellular matrix components, basement
membranes, the limited availability of nutrients and oxygen, and
attack by the immune system [29]. Furthermore, tumor progression
toward metastasis requires a further defense against microenviron-
mental death stimuli, such as nutrient deprivation and hypoxia,
alterations in extracellular adhesions, changes in cell shape during
invasion and exposure to novel stromal microenvironments [29].
Therefore, O-GlcNAcylation elevation might be “beneﬁcial” for cancer
cells to protect against a wide range of apoptotic stimuli, promotingtment signiﬁcantly enhanced the cell invasion ofA549 cells, andOGT silencing inhibited the
ion of H1299 (B) and HT29 cells (C). **Pb0.01, ***Pb0.001 (Student's t-test), mean±SEM.
519W. Mi et al. / Biochimica et Biophysica Acta 1812 (2011) 514–519tumor formation and progression. At the same time, the protective
effects of O-GlcNAcylationmay also reduce tumor sensitivity to ionizing
radiation and a number of DNA damaging chemotherapeutic agents.
Thus, O-GlcNAcylation suppression, in combination with radiation and
the conventional antitumor agents, may be of clinical interest for
treatment of certain types of tumors.
5. Conclusion
In this study, immunohistochemical studies indicated that O-
GlcNAcylation and OGT of lung and colon cancer tissues were
signiﬁcantly elevated compared with that in the corresponding
adjacent tissues. Furthermore, soft agar assay demonstrated that O-
GlcNAcylation could enhance the anchorage-independent growth of
lung and colon cancer cells. However, O-GlcNAcylation might play
different roles in invasion depending on cancer cellular context.
Altogether, these results suggest that O-GlcNAcylation might play
important roles in lung and colon cancer formation and progression,
and may be a valuable target for diagnosis and therapy of cancer.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2011.01.009.
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